



# Rystiggo in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

NEUROLOGY · GMG (AChR+ OR MUSK+)

## The clinical situation

Rystiggo (rozanolixizumab-noli) is an FDA-approved FcRn antagonist for generalised myasthenia gravis (gMG) in adults who are AChR-antibody positive or MuSK-antibody positive, manufactured by UCB. Rystiggo is notable as one of the first FcRn antagonists with a specific MuSK-positive indication — a clinically distinct and often more severe gMG subtype. Administration is a weekly ~15-minute subcutaneous infusion for six weeks (one cycle), with additional cycles initiated per clinical response. Eligibility requires confirmed AChR- or MuSK-antibody seropositivity, MGFA classification, and pre-treatment screening.

## The pathway, 6 steps

- 1 Consultation with neurology.** AChR or MuSK antibody confirmation, gMG diagnosis, MGFA classification, and pre-treatment screening documented.
- 2 Administration facility identification.** Clinic or infusion centre able to deliver subcutaneous infusions and manage any reaction.
- 3 SFDA named-patient application.** Physician files clinical letter, patient identifier, and product details.
- 4 US-side sourcing.** Reserve Meds coordinates through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Cold-chain shipment.** Rystiggo ships at 2–8°C with continuous temperature monitoring.
- 6 Arrival & cycle administration.** Licensed facility delivers the six-weekly cycle; further cycles per clinical response.

## Indicative economics

**Reference US cash-pay range:** USD 400,000–600,000 annualised depending on cycle frequency (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

## Indicative first-dose timing

**7–14 days** from a complete SFDA application to first cycle, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review, keyed to the AChR- or MuSK-positive gMG rationale. **Logistics.** 2–8°C cold-chain coordination. **Concierge case lead.** Named point of contact across cycles. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Rystiggo × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/rystiggo-saudi-arabia.html](https://reservemed.com/access-guides/rystiggo-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team